Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 5/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9326107 | 0.94 | NOD1 (0.50) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL2545708 | 0.87 | NOD1 (0.48) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL2545697 | 0.87 | NOD1 (0.48) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL30830405 | 0.87 | NOD1 (0.48) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL441159 | 0.87 | NOD1 (0.45) | NOD1DPP4 | |
| SCHEMBL10704006 | 0.81 | NOD1 (0.44) | NOD1ITGB1ITGA4ACEDPP4 | |
| SCHEMBL28610885 | 0.81 | SLC7A5 (0.50) | NOD1ITGB1ITGA4SLC7A5 | |
| SCHEMBL29430141 | 0.80 | FNTA (0.37) | NOD1ACE | |
| SCHEMBL10621766 | 0.78 | NOD1 (0.37) | NOD1ITGB1ITGA4ACEKIF11 | |
| N-Monoacetylcystine SCHEMBL468824 | 0.78 | MAPT (0.48) | NOD1ITGB1ITGA4NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110418837-B | Culture medium comprising oligopeptides | 赢创运营有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3372671-B1 | CULTURE MEDIUM COMPRISING OLGOPEPTIDES | EVONIK OPERATIONS GMBH (DE) | 2021-11-03 | — | — | EP | disclosed |
| EP-1144613-B2 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2018162346-A1 | CULTURE MEDIUM COMPRISING OLIGOPEPTIDES | EVONIK TECHNOCHEMIE GMBH (DE) | 2018-09-13 | — | — | WO | disclosed |
| EP-3372671-A1 | CULTURE MEDIUM COMPRISING OLGOPEPTIDES | Evonik Technochemie GmbH (DE) | 2018-09-12 | — | — | EP | disclosed |
| US-20170362626-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20160244798-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2016-08-25 | — | — | US | disclosed |
| EP-2305804-B1 | MonoPEGylated human growth hormone | BOLDER BIOTECHNOLOGY INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8957023-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8932828-B2 | Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins | BOLDER BIOTECHNOLOGY, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2001087925-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1144613-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042175-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0399656-B1 | Nutrient compositions for amino acid supplementation in mammals | KYOWA HAKKO KOGYO KK (JP) | 1994-02-02 | — | — | EP | disclosed |
| US-5102871-A | Admistering glutamy-cystine and or glutamyl-cysteine disulfide to a mammal to increase in vivo level of cysteine | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0264953-B1 | USE OF N,N'-BIS-L-AMINO ACID-L-CYSTIN PEPTIDES IN AMINO ACID PREPARATIONS FOR ORAL AND PARENTERAL ADMINISTRATION | PFRIMMER KABI GMBH & CO. KG (DE) | 1991-05-08 | — | — | EP | disclosed |
| EP-0399656-A1 | Nutrient compositions for amino acid supplementation in mammals | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1990-11-28 | — | — | EP | disclosed |
| US-4968696-A | CHRONIC UREMIA OR HEPATIC CIRRHOSIS | PFRIMMER + CO. PHARMAZEUTISCHE WERKE ERLANGEN GMBH + CO. KG (DE) | 1990-11-06 | — | — | US | disclosed |
| WO-1988003150-A2 | N,N'-BIS-AMINO ACID-L-CYSTINE-PEPTIDE-CONTAINING AMINO ACID PREPARATIONS FOR ORAL AND PARENTERAL ADMINISTRATION | PFRIMMER + CO. PHARMAZEUTISCHE WERKE ERLANGEN GMBH (DE) | 1988-05-05 | — | — | WO | disclosed |
| EP-0264953-A2 | Use of N,N'-bis-L-amino acid-L-cystin peptides in amino acid preparations for oral and parenteral administration | PFRIMMER KABI GMBH & CO. KG (DE) | 1988-04-27 | — | — | EP | disclosed |